Phase I Study of Daily Irinotecan as a Radiation Sensitizer for Locally Advanced Pancreatic Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 2, 2010, Pages 409-413

  de la Fouchardière, Christelle ^a   Négrier, Sylvie ^a   Labrosse, Hugues ^b   Martel Lafay, Isabelle ^a   Desseigne, Françoise ^a   Méeus, Pierre ^a   Tavan, David ^b   Petit Laurent, Fabien ^c   Rivoire, Michel ^a   Pérol, David ^a   Carrie, Christian ^a  

^a UNIVERSITÉ DE LYON   (France)

^b Infirmerie Protestante   (France)

^c CENTRE HOSPITALIER   (France)

Author keywords

Irinotecan; Pancreas; Radiation therapy

Indexed keywords

ADENOCARCINOMA OF THE PANCREAS; DOSE LEVELS; DOSE LIMITING TOXICITY; HYPOKALEMIA; IRINOTECAN; MAXIMUM TOLERATED DOSE; MEDIAN SURVIVAL; MULTI-DISCIPLINARY TEAMS; PANCREATIC CANCERS; PHASE I; PROGRESSION FREE SURVIVAL; RADIATION SENSITIZERS; RADIATION THERAPY; TOTAL DOSE; TUMOR VOLUMES;

RADIOTHERAPY; TOXICITY;

DRUG PRODUCTS;

ANALGESIC AGENT; IRINOTECAN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPOKALEMIA; LAPAROTOMY; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOSENSITIZATION; SEPTIC SHOCK; STOMACH ULCER; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; CAMPTOTHECIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; SURVIVAL ANALYSIS;

EID: 77951975182     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.05.008     Document Type: Article

References (21)

1. Yeo C.J., Yeo T.P., and Hruban R.H. Cancer of the pancreas. In: DeVita V.T.J., Hellman S., and Rosenberg S.A. (Eds). Cancer: Principles and practice of oncology. 5th ed (2005), Lippincott-Raven, Philadelphia 1054-1084
2. Wisinski K.B., Wahl A.O., Small Jr. W., et al. Inoperable pancreatic cancer: Standard of care. Oncology 21 (2007) 1558-1564
3. Dickler A., and Abrams R.A. Radiochemotherapy in the management of pancreatic cancer-Part II: Use in adjuvant and locally unresectable settings. Semin Radiat Oncol 15 (2005) 235-244
4. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48 (1981) 1705-1710
5. Poggi M.M., Kroog G.S., Russo A., et al. Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 54 (2002) 670-676
6. Chauffert B., Mornex F., Bonnetain F., et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19 (2008) 1592-1599
7. Boothman D.A., Trask D.K., and Pardee A.B. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. Cancer Res 49 (1989) 605-612
8. Mattern M.R., Hofmann G.A., McCabe F.L., et al. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 51 (1991) 5813-5816
9. Minsky B.D., O'Reilly I., and Wang D. Daily low dose irinotecan (CPT11) plus pelvis irradiation as preoperative treatment of locally advanced rectal cancer. [Abstract 1023]. Proc Am Soc Clin Oncol 18 (1999) 266
10. Konstadoulakis M.M., Antonakis P.T., Tsibloulis B.G., et al. A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 48 (2001) 417-420
11. Taieb J., Lecomte T., Aparicio T., et al. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: Results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol 18 (2007) 498-503
12. Jansman F.G., Sleijfer D.T., de Graaf J.C., et al. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf 24 (2001) 353-367
13. ICRU Report 62 (1999), International Commission on Radiation Units & Measurements, Bethesda (MD)
14. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
15. Iles S., Gollins S., Susnerwala S., et al. Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: A phase I/II study. Br J Cancer 98 (2008) 1210-1216
16. Grabenbauer G.G., Buchfelder M., Schrell U., et al. Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma. Front Radiat Ther Oncol 33 (1999) 364-368
17. Terret C., Couteau C., and Armand J.P. CPT-11: The European clinical development. J Infus Chemother 6 (1996) 152-157
18. Yip D., Karapetis C., Strickland A., et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 3 (2006) CD002093
19. Klaassen D.J., MacIntyre J.M., Catton G.E., et al. Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-An Eastern Cooperative Oncology Group study. J Clin Oncol 3 (1985) 373-378
20. Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23 (2005) 3509-3516
21. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80 (1988) 751-755